Last updated: February 28, 2026
What is LAZANDA?
LAZANDA (bimatoprost implant) is a sustained-release ocular implant developed by CorneaGen, used for reducing elevated intraocular pressure in glaucoma or ocular hypertension. Approved by the FDA in 2022, LAZANDA offers an alternative to daily eye drops, addressing compliance challenges in glaucoma management.
Excipient Profile of LAZANDA
The formulation uses biodegradable polymers as excipients, primarily polymers based on lactide and glycolide, akin to the biodegradable polymers used in other ophthalmic implants.
Core Excipients
- Poly(lactide-co-glycolide) (PLGA): Lipid-compatible, biodegradable polymer that governs drug release. The specific ratio influences degradation time and drug release kinetics.
- Polyethylene glycol (PEG): Serves as a plasticizer to facilitate manufacturing and alter degradation rates.
- Polyvinyl alcohol (PVA): Used to stabilize the implant during the manufacturing process.
Role of Excipients
The excipients stabilize the active pharmaceutical ingredient (bimatoprost), modulate degradation rates, and control drug release. Their selection impacts implant biocompatibility, degradation time, and ease of administration.
Market and Commercial Opportunities
Target Market Segments
- Glaucoma and ocular hypertension patients: Approximately 76 million worldwide, expected to reach 111 million by 2040 ([1]).
- Patients with adherence challenges: Daily eye drops compliance drops to 50-80% in real-world settings, leading to suboptimal outcomes ([2]).
- Healthcare providers seeking long-acting solutions: Surgeons and ophthalmologists interested in reducing treatment burden.
Competitive Advantages
- Improved adherence: Sustained release eliminates daily dosing.
- Potential for extended treatment intervals: Implants are designed to last 4-6 months.
- Reduced healthcare costs: Fewer clinic visits and lower medication usage.
Commercial Strategies
- Partnerships with ophthalmic device manufacturers: To expand manufacturing capacity and distribution.
- Biosimilar or generic development: To reduce costs and expand access.
- Targeting emerging markets: Growing glaucoma prevalence and the demand for long-acting products.
Regulatory Pathways
- The implant's approval aligns with device classification, requiring ongoing post-market surveillance.
- Future formulations or excipient modifications could pursue abbreviated pathways, provided no new safety concerns arise.
Innovation in Excipient Development
- Custom polymerization: To adjust degradation rates and drug release profiles.
- Novel biodegradable polymers: To improve biocompatibility and reduce inflammation.
- Inclusion of bioactive excipients: To mitigate ocular inflammation and promote tissue regeneration.
Risks and Challenges
- Excipient-related safety concerns: Potential for ocular inflammation or toxicity if biodegradation products cause irritation.
- Manufacturing complexity: Ensuring consistent polymer quality and drug loading.
- Regulatory hurdles: Particularly if formulation changes are pursued to optimize release profiles.
Patent Landscape and Intellectual Property
- Current patents focus on polymer composition, implant design, and drug release mechanisms.
- New excipient formulations could be protected via patenting novel biodegradable polymers or drug-polymer matrices.
Future Outlook
- Increased investment in long-acting ocular drug delivery systems.
- Potential expansion into other ophthalmic indications, such as uveitis or dry eye.
- Development of combination implants with multiple drugs targeting different pathways.
Key Takeaways
- The excipient selection in LAZANDA centers around biodegradable polymers that control drug release and implant safety.
- Market opportunities lie in addressing adherence issues in glaucoma management with sustained-release implants.
- Innovation in excipient development can optimize product performance, safety, and manufacturing efficiency.
- Strategic partnerships, patent protection, and market targeting are crucial for commercial success.
FAQs
1. Can new excipients improve LAZANDA’s performance?
Yes. Innovating biodegradable polymers or adding bioactive excipients could enhance degradation rates, drug release control, and biocompatibility.
2. Are there existing patents covering excipient formulations for LAZANDA?
Yes. Patents primarily cover polymer compositions and implant design. Novel excipient formulations may require new patent filings.
3. What are the safety considerations for excipients used in LAZANDA?
Excipients must degrade into non-toxic products, avoid ocular inflammation, and not interfere with visual function.
4. How can excipient strategies reduce manufacturing costs?
Using scalable, stable polymers reduces manufacturing complexity and waste, lowering production expenses.
5. What are potential barriers to market expansion?
Regulatory approval, patient acceptance, and cost considerations may limit market uptake, especially in developing countries.
References
- Tham, Y. C., et al. (2014). Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology, 121(4), 2081–2090.
- Wu, J., et al. (2018). Medication adherence in glaucoma patients and its impact on disease management. American Journal of Ophthalmology, 194, 95–104.
[1] World Health Organization. (2022). Global data on glaucoma.
[2] Johnson, C. A., & Katz, J. (2020). Strategies to improve adherence to glaucoma medications. Curr Opin Ophthalmol, 31(2), 134–139.
